623 related articles for article (PubMed ID: 25398516)
21. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.
Woo JA; Chen LN; Bhagat A; Oermann EK; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2014; 4():122. PubMed ID: 24904833
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison.
Ogita M; Yamashita H; Nozawa Y; Ozaki S; Sawayanagi S; Ohta T; Nakagawa K
Radiat Oncol; 2021 Jun; 16(1):107. PubMed ID: 34118956
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
Hannan R; Tumati V; Xie XJ; Cho LC; Kavanagh BD; Brindle J; Raben D; Nanda A; Cooley S; Kim DWN; Pistenmaa D; Lotan Y; Timmerman R
Eur J Cancer; 2016 May; 59():142-151. PubMed ID: 27035363
[TBL] [Abstract][Full Text] [Related]
25. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.
Arscott WT; Chen LN; Wilson N; Bhagat A; Kim JS; Moures RA; Yung TM; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Jul; 9():163. PubMed ID: 25056726
[TBL] [Abstract][Full Text] [Related]
26. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
[TBL] [Abstract][Full Text] [Related]
28. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.
Ju AW; Wang H; Oermann EK; Sherer BA; Uhm S; Chen VJ; Pendharkar AV; Hanscom HN; Kim JS; Lei S; Suy S; Lynch JH; Dritschilo A; Collins SP
Radiat Oncol; 2013 Jan; 8():30. PubMed ID: 23369294
[TBL] [Abstract][Full Text] [Related]
30. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
31. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
Front Oncol; 2016; 6():122. PubMed ID: 27242962
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
Chen LN; Suy S; Wang H; Bhagat A; Woo JA; Moures RA; Kim JS; Yung TM; Lei S; Collins BT; Kowalczyk K; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Jun; 9():148. PubMed ID: 24966110
[TBL] [Abstract][Full Text] [Related]
33. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results.
Bolzicco G; Favretto MS; Scremin E; Tambone C; Tasca A; Guglielmi R
Technol Cancer Res Treat; 2010 Oct; 9(5):473-7. PubMed ID: 20815418
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
35. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
Zilli T; Franzese C; Guckenberger M; Giaj-Levra N; Mach N; Koutsouvelis N; Achard V; Mcdonald A; Alongi F; Scorsetti M; Constantin G; Bertaut A; Miralbell R
Radiother Oncol; 2024 May; 194():110181. PubMed ID: 38403022
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.
Jeong BK; Jeong H; Ha IB; Choi HS; Kam SC; Hwa JS; Hyun JS; Chung KH; Choi SM; Kang KM
J Korean Med Sci; 2015 Jun; 30(6):710-5. PubMed ID: 26028922
[TBL] [Abstract][Full Text] [Related]
38. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
39. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
[TBL] [Abstract][Full Text] [Related]
40. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
